Amgen bought ChemoCentryx ChemoCentryx from 10/20/22

User image

Vladimir Petenev

News editor
press@blackterminal.com

Amgen completed its acquisition of ChemoCentryx for $3.7 billion, or $52 per share.

ChemoCentryx

Review

Source:

{source} pictogram

investors.amgen.com

Vladimir Petenev

News editor

Write your comment first

News feed

Shareholders of Rosbank approved dividends for 2022

5/30/23 ROSB

Board of Directors of Novorossiysk Bakery Products Plant recommended that dividends be paid for 2022

5/30/23 NKHP

KGC reported for 3 months of 2023 by RAS

5/30/23 KGKC

Eurotrans plans to enter the Moscow Exchange in the fall of 2023

5/30/23 EUTR

VTB started collecting applications for an additional issue of shares

5/30/23 VTBR

Shareholders of Donskoy Factory of Radiocomponents approved dividends for 2022

5/30/23 DZRD

Sales of Etalon Group in Q1 fell by 18.6%

5/30/23 ETLN

SFI reported for 3 months of 2023 by IFRS

5/30/23 SFIN

IDGC of Urals reported for 3 months of 2023 by IFRS

5/30/23 MRKU

Board of Directors of Rosneft Oil Company recommended that dividends be paid for 2022

5/30/23 ROSN